Eledon Pharmaceuticals (ELDN) Net Income towards Common Stockholders (2016 - 2017)
Historic Net Income towards Common Stockholders for Eledon Pharmaceuticals (ELDN) over the last 5 years, with Q1 2017 value amounting to -$3.9 million.
- Eledon Pharmaceuticals' Net Income towards Common Stockholders rose 6616.49% to -$3.9 million in Q1 2017 from the same period last year, while for Sep 2017 it was -$7.6 million, marking a year-over-year increase of 8319.37%. This contributed to the annual value of -$36.4 million for FY2024, which is 6883.4% up from last year.
- Per Eledon Pharmaceuticals' latest filing, its Net Income towards Common Stockholders stood at -$3.9 million for Q1 2017, which was up 6616.49% from -$3.7 million recorded in Q4 2016.
- Over the past 5 years, Eledon Pharmaceuticals' Net Income towards Common Stockholders peaked at -$3.7 million during Q4 2016, and registered a low of -$13.5 million during Q2 2016.
- In the last 5 years, Eledon Pharmaceuticals' Net Income towards Common Stockholders had a median value of -$7.7 million in 2014 and averaged -$8.3 million.
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first plummeted by 17357.13% in 2015, then skyrocketed by 6616.49% in 2017.
- Quarter analysis of 5 years shows Eledon Pharmaceuticals' Net Income towards Common Stockholders stood at -$5.5 million in 2013, then dropped by 12.06% to -$6.2 million in 2014, then plummeted by 77.46% to -$11.0 million in 2015, then surged by 66.08% to -$3.7 million in 2016, then dropped by 3.45% to -$3.9 million in 2017.
- Its Net Income towards Common Stockholders stands at -$3.9 million for Q1 2017, versus -$3.7 million for Q4 2016 and -$9.3 million for Q3 2016.